Quantcast
Last updated on April 23, 2014 at 11:31 EDT

Latest antibodies Stories

2013-12-09 12:25:49

- Preclinical Research with Novel, Highly Specific Mouse anti-iNKT Antibodies Presented at American Society of Hematology Meeting WALTHAM, Mass., Dec. 9, 2013 /PRNewswire/ -- NKT Therapeutics (NKTT) today presented research results with NKT14 and NKT14m, monoclonal antibodies designed to deplete (NKT14) or activate (NKT14m) murine iNKT cells. The results from these studies demonstrate that NKT14 can produce a complete and long lasting depletion of both peripheral blood and tissue...

2013-12-06 11:25:58

Findings could reshape research on cancer origins and treatment of other autoimmune diseases Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage. A report on the discovery, published in the Dec. 5 issue of Science, also suggests that a normal immune system is critical for preventing the development of common types of cancer. According to researchers,...

2013-12-06 08:24:19

Collaboration to Explore Recombinant Human-Derived Monoclonal Antibodies Targeting Misfolded SOD1 CAMBRIDGE, Mass., Dec. 6, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease. The research partnership will explore a human monoclonal antibody...

2013-12-05 23:23:43

RnRMarketResearch.com adds “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) – Global Forecast to 2018” to its store. Dallas, Texas (PRWEB) December 05, 2013 The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant...

2013-12-05 16:25:31

- KB004, experimental anti-EphA3 monoclonal antibody therapeutic, in clinical development against hematologic cancers SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a composition of matter patent covering certain antibodies targeting EphA3, including KaloBios' experimental anti-cancer monoclonal antibody (mAb), KB004. The allowed claims...

2013-12-03 08:33:10

Tolera seeking partner for lead Ph2/Ph3 asset for solid organ transplantation KALAMAZOO, Mich., Dec. 3, 2013 /PRNewswire/ -- Tolera Therapeutics, Inc., a privately-held, immune therapy company developing a novel T-cell targeted therapeutic platform, announced today that it has appointed Ashleigh Palmer as President, CEO and Board Director. Tolera's Chairman, Suzette Dutch, Managing Partner of Triathlon Medical Ventures, said, "Ashleigh has an ideal track record in developing,...

2013-12-03 08:31:26

Full article: http://bit.ly/EpiVax_Biotest DREIEICH, Germany and PROVIDENCE, R.I., Dec. 3, 2013 /PRNewswire/ -- Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for Hemophilia therapy will be altered in such a way that the immune system of the patients may not respond by...

Nanomedicine May One Day Be Delivered Orally
2013-11-28 04:43:35

redOrbit Staff & Wire Reports - Your Universe Online Researchers from MIT and Brigham and Women's Hospital (BWH) have developed a new type of nanoparticle that can be absorbed through the digestive tract, bringing the cutting-edge treatment method one-step closer to being administered orally instead of through injections. While drugs delivered by nanoparticles could help treat cancer, diabetes and several other types of disease, the fact that these particles currently have to be...

2013-11-27 12:24:07

DUBLIN, November 27, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/7lgrpn/flatrate) has announced the addition of the "Flat-Rate Subscription to La Merie Publishing Reports" [http://www.researchandmarkets.com/research/7lgrpn/flatrate ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This subscription provides access during one year to all existing and new reports produced by La Merie Publishing...

Decoding An Individual's Immune System
2013-11-21 15:12:21

University of California - Santa Barbara You may be sensitive to gluten, but you're not sure. Perhaps you can't put your finger on a recurring malaise, and your doctor is at a loss to figure it out. A diagnostic method recently developed by UC Santa Barbara professor Patrick Daugherty can reveal — on a molecular level — the factors behind conditions thought to have environmental triggers. By decoding an individual's immune system, this elegant and accurate method can demystify,...